Fibromyalgia, Trigger Points
Conditions
Keywords
Body Composition, Autonomic Nervous System, Oxygen, Randomized Controlled Trial
Brief summary
This study evaluates the benefits of dry needling in trigger points on autonomic nervous system, photoelectric plethysmography, body composition in patients with fibromyalgia syndrome.
Detailed description
Dru needling can be developed on active trigger points. Myofascial trigger points can be active or latent. An active myofascial trigger point pain causes giving a specific pathological picture. We will conduct a location of myofascial trigger points following the illustrations location myofascial trigger points that indicate Travell and Simons both left-sided and right.
Interventions
OTHERDry Needling Therapy
The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
Sponsors
Universidad de Almeria
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Fibromyalgia syndrome diagnosis. * Aged from 18 to 65 years. * No regular physical activity. * Limitation of usual activities due to pain on at least 1 day in the previous 30 days. * Agreement to attend evening therapy sessions.
Exclusion criteria
* Severe physical disability. * Comorbid conditions (eg, morbid obesity, inflammatory diseases, irritable bowel syndrome, interstitial cystitis). * Uncontrolled endocrine disorders (eg, hyperthyroidism or hypothyroidism, diabetes). * Malignancy. * Psychiatric. * Illnesses (eg, schizophrenia or substance abuse). * Medication usage other than as-needed analgesics (excluding long-term narcotics). * History of surgery. * History of whiplash injury. * Presence of a score \>9 points in the Beck Depression Inventory.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes Scores on Visual Analoge Scale | At baseline and 4 weeks | Intensity of pain (within McGill questionnaire) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change Scores on Body Composition | At baseline and 4 weeks | Fat mass. Body fat mass. Intracellular water. Extracellular water. Fat-free mass. Total body water. |
| Changes Scores on Cholinergic response indicators (%). | At baseline and 4 weeks | — |
| Changes Scores on Heart rate variability. | At baseline and 4 weeks | — |
| Changes Scores on Valsalva ratio. K30/15. | At baseline and 4 weeks | — |
| Changes Scores on Percentage Evaluation Peripheral Capillary Oxygen saturation and photoelectric plethysmograph (Analysis of pulse wave and PANI) | At baseline and 4 weeks | Cardiac output. Reflectivity index. Stiffness index. Oxygen saturation. |
| Changes Scores on Systolic pressure. | At baseline and 4 weeks | — |
| Changes Scores on Diastolic pressure. | At baseline and 4 weeks | — |
| Changes Scores on Assessment of autonomic nervous system | At baseline and 4 weeks | Galvanic response estimate. |
| Changes Scores on Systemic vascular resistance. | At baseline and 4 weeks | — |
Countries
Spain
Outcome results
None listed